Mico BioMed Sets IPO Price at 15,000 KRW... Scheduled for KOSDAQ Listing on the 22nd
523 Institutions Participated, Competition Rate 159.15 to 1
High Evaluation of Lap-on-a-Chip Technology and COVID-19 Diagnostic Equipment Benefits,
[Asia Economy Reporter Eunmo Koo] Bio medical diagnostic company Micobiomed has set its public offering price at the upper end of the desired band (12,000~15,000 KRW), finalizing it at 15,000 KRW.
Micobiomed conducted demand forecasting targeting domestic and international institutional investors over two days on the 6th and 7th, and announced on the 12th that a total of 523 institutions participated, recording a competition rate of 159.15 to 1. The total public offering amount is approximately 37.5 billion KRW.
A representative from KB Securities, the lead underwriter, stated, “The market showed strong interest due to the merit of being able to diagnose various viruses not only COVID-19 but also post-COVID-19, and especially overseas institutions responded highly, proving the elevated status of K-Bio achieved through COVID-19 quarantine success. In particular, the long-term growth momentum based on the core technology of 'Lab-on-a-Chip' was recognized as excellent, and the corporate value was highly evaluated.”
Micobiomed operates its business focusing on three areas: molecular diagnostics, biochemical diagnostics, and immunodiagnostics. It provides solutions optimized for point-of-care testing (POCT) and has established itself as a key player in the diagnostic market. Additionally, it quickly responded to the COVID-19 pandemic, successfully securing new revenue sources, and is expected to see profitability growth along with corporate volume expansion in the future.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- [Breaking] President Lee: "Korea and Japan Agree on the Need for Rapid Restoration of Peace and Stability in the Middle East"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Kim Sung-woo, CEO of Micobiomed, said, “Despite the difficult environment with various variables such as market deterioration due to the COVID-19 situation, we were able to successfully complete demand forecasting thanks to the interest of investors. Recognizing the steady interest in the market, we will carry out management responsibly as a listed company.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
